Conatus Pharma (CNAT) became Histogen (HSTO) via reverse merger

• Jan 2020: After its Novartis-partnered nonalcoholic steatohepatitis (NASH) drug failed a third midphase trial, Conatus Pharma (CNAT) unveiled a plan to lay off 40% of its staffers. Then the company has found its lifeline—a reverse merger with regenerative medicine player Histogen (HSTO). 

   

Conatus Pharma (CNAT) to present at the International Liver Congress 2019

• Conatus Pharma (CNAT) announced today the acceptance of an abstract for a late-breaker oral presentation at The International Liver Congress 2019. The oral presentation will detail results from the company's Phase 2b ENCORE-PH clinical trial of emricasan in patients with NASH cirrhosis and severe portal hypertension. 

 

SAN DIEGO, March 13, 2019 (GLOBE NEWSWIRE) -- Conatus Pharmaceuticals Inc. (CNAT) announced today the acceptance of an abstract for a late-breaker oral presentation at The International Liver Congress™ 2019, the Annual Meeting of the European Association for the Study of the Liver (EASL) in Vienna, Austria, April 10-14.

The oral presentation at EASL entitled, “Multicenter, Double-blind, Placebo-controlled, Randomized Trial of Emricasan in Subjects with NASH Cirrhosis and Severe Portal Hypertension (PH),” (#LB01) will detail results from the company’s Phase 2b ENCORE-PH clinical trial of emricasan, the company’s first-in-class, orally active pan-caspase protease inhibitor. Guadalupe Garcia-Tsao, M.D., Professor of Medicine in the Section of Digestive Diseases at Yale School of Medicine, Director of the Clinical and Translational Core at Yale Liver Center, Chief of the Section of Digestive Diseases at the Veterans Administration-Connecticut Health Care System, and the central reader in the ENCORE-PH trial, will deliver the presentation on Saturday, April 13, at 4:00 p.m. CEST.

Conatus Pharmaceuticals (CNAT) began trading on the NASDAQ on 24 July 2013

Description

Conatus Pharmaceuticals Inc. is a biotechnology company focused on the development and commercialization of medicines to treat liver disease. The Company is developing its lead compound, emricasan, for the treatment of patients in orphan populations with chronic liver disease and acute exacerbations of chronic liver disease. The Company has designed a clinical program to demonstrate the therapeutic benefit of emricasan across the spectrum of fibrotic liver disease. The Company’s initial development strategy targets indications for emricasan with high unmet clinical need in orphan patient populations, such as patients with acute-on-chronic liver failure (ACLF), chronic liver failure (CLF), and patients who have developed liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection (HCV-POLT).

Products include Emricasan, an orally active caspase protease inhibitor for the treatment of acute-on-chronic liver failure and chronic liver failure, as well as for the patients who have developed liver fibrosis post-orthotopic liver transplant due to Hepatitis C virus infection. The company was founded in 2005 and is headquartered in San Diego, California.

Address

Suite 200, 4365 Executive Drive
SAN DIEGO, CA 92121
United States

Website 

www.conatuspharma.com

Key stats and ratios

	Q2 (Jun '13)	2012
Net profit margin	-	-
Operating margin	-	-
EBITD margin	-	-
Return on average assets	-372.19%	-69.70%
Return on average equity	-	-
Employees	13